Dystrophin (DMD) - Pipeline Review, H2 2016

Publisher Name :
Date: 31-Aug-2016
No. of pages: 81
Price : Single User: US $ 3500  US $ 2800 Corporate User: US $ 10500  US $ 7875
This report is available at upto 25% Discount till 02 June 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Note*:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Global Markets Direct's, ‘Dystrophin (DMD) - Pipeline Review, H2 2016', provides in depth analysis on Dystrophin (DMD) targeted pipeline therapeutics.

The report provides comprehensive information on the Dystrophin (DMD), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Dystrophin (DMD) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Dystrophin (DMD)

  • The report reviews Dystrophin (DMD) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in Dystrophin (DMD) targeted therapeutics and enlists all their major and minor projects

  • The report assesses Dystrophin (DMD) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to Dystrophin (DMD) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for Dystrophin (DMD)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Dystrophin (DMD) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

This report is available at upto 25% Discount till 02 June 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Dystrophin (DMD) - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Dystrophin (DMD) Overview 8
Therapeutics Development 9
Dystrophin (DMD) - Products under Development by Stage of Development 9
Dystrophin (DMD) - Products under Development by Therapy Area 10
Dystrophin (DMD) - Products under Development by Indication 11
Dystrophin (DMD) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Dystrophin (DMD) - Products under Development by Companies 14
Dystrophin (DMD) - Products under Development by Universities/Institutes 16
Dystrophin (DMD) - Therapeutics Assessment 18
Assessment by Monotherapy/Combination Products 18
Assessment by Mechanism of Action 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Dystrophin (DMD) - Companies Involved in Therapeutics Development 24
Asklepios BioPharmaceutical, Inc. 24
BioMarin Pharmaceutical Inc. 25
Daiichi Sankyo Company, Limited 26
Genethon 27
Nippon Shinyaku Co., Ltd. 28
PTC Therapeutics, Inc. 29
Sarepta Therapeutics, Inc. 30
WAVE Life Sciences Ltd. 31
Dystrophin (DMD) - Drug Profiles 32
Antisense Oligonucleotide 1 to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Antisense Oligonucleotide to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Antisense Oligonucleotide to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Biostrophin - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
BMBD-001 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
DS-5141 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
eteplirsen - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Gene Therapy to Activate Dystrophin for Muscular Dystrophy - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
NS-065 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Oligonucleotide to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Oligonucleotides 1 to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Oligonucleotides 2 to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Oligonucleotides 3 to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
PRO-055 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
SGT-001 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Small Molecule to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
SRP-4008 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
SRP-4044 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
SRP-4045 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
SRP-4050 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
SRP-4052 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
SRP-4053 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
SRP-4055 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Stem Cell Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Dystrophin (DMD) - Dormant Projects 69
Dystrophin (DMD) - Discontinued Products 70
Dystrophin (DMD) - Featured News & Press Releases 71
Jun 06, 2016: Sarepta Therapeutics Announces FDA Request For Dystrophin Data Prior To Making A Decision on Eteplirsen NDA 71
May 25, 2016: Sarepta Therapeutics Announces FDA Will Not Complete the Review of the Eteplirsen New Drug Application By The PDUFA Date 71
Apr 25, 2016: MDA Chief Medical and Scientific Officer Testifies at Landmark FDA Hearing for Duchenne Drug 71
Apr 25, 2016: Sarepta Issues Statement on Advisory Committee Outcome for Use of Eteplirsen in the Treatment of Duchenne Muscular Dystrophy 72
Mar 14, 2016: Sarepta Therapeutics Announces FDA Advisory Committee Meeting to Review Eteplirsen 73
Mar 14, 2016: Sarepta Therapeutics Announces FDA Advisory Committee Meeting to Review Eteplirsen as a Treatment for Duchenne Muscular Dystrophy 73
Feb 25, 2016: Daiichi Sankyo Announces Commencement of Clinical Trials in Japan for Duchenne Muscular Dystrophy Treatment 73
Feb 08, 2016: Sarepta Therapeutics Receives Notification of PDUFA Extension for Eteplirsen 74
Jan 20, 2016: FDA Postpones Advisory Committee Meeting to Review Eteplirsen Due to Severe Weather Storm in the Washington D.C. Area 74
Dec 18, 2015: Sarepta Therapeutics Announces FDA Advisory Committee Meeting to Review Eteplirsen as a Treatment for Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping 75
Nov 17, 2015: Sarepta Therapeutics Announces Publication of Positive Long-Term Safety and Efficacy Data for Eteplirsen in the Annals of Neurology 75
Oct 22, 2015: Gene Therapy Treats All Muscles in the Body in Muscular Dystrophy Dogs 76
Oct 14, 2015: Sarepta Therapeutics Announces Tentative FDA Advisory Committee Meeting to Review Eteplirsen as a Treatment for Duchenne Muscular Dystrophy 77
Oct 01, 2015: Sarepta Therapeutics Announces Additional Long-Term Efficacy and Safety Data from Pivotal Phase IIb Program of Eteplirsen for Treatment of Duchenne Muscular Dystrophy 77
Aug 25, 2015: Sarepta Therapeutics Announces FDA Has Filed Eteplirsen NDA for the Potential Treatment of Duchenne Muscular Dystrophy for Patients Amenable to Exon 51 Skipping 79
Appendix 80
Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 80
Disclaimer 81

List of Tables

Number of Products under Development for, H2 2016 9
Number of Products under Development by Therapy Area, H2 2016 10
Number of Products under Development by Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Products under Development by Companies, H2 2016 15
Number of Products under Investigation by Universities/Institutes, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Assessment by Monotherapy/Combination Products, H2 2016 18
Number of Products by Stage and Mechanism of Action, H2 2016 19
Number of Products by Stage and Route of Administration, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 23
Pipeline by Asklepios BioPharmaceutical, Inc., H2 2016 24
Pipeline by BioMarin Pharmaceutical Inc., H2 2016 25
Pipeline by Daiichi Sankyo Company, Limited, H2 2016 26
Pipeline by Genethon, H2 2016 27
Pipeline by Nippon Shinyaku Co., Ltd., H2 2016 28
Pipeline by PTC Therapeutics, Inc., H2 2016 29
Pipeline by Sarepta Therapeutics, Inc., H2 2016 30
Pipeline by WAVE Life Sciences Ltd., H2 2016 31
Dormant Projects, H2 2016 69
Discontinued Products, H2 2016 70

List of Figures

Number of Products under Development for, H2 2016 9
Number of Products under Development by Therapy Area, H2 2016 10
Number of Products under Development by Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy/Combination Products, H2 2016 18
Number of Products by Stage and Mechanism of Actions, H2 2016 19
Number of Products by Routes of Administration, H2 2016 20
Number of Products by Stage and Routes of Administration, H2 2016 20
Number of Products by Molecule Types, H2 2016 22
Number of Products by Stage and Molecule Type, H2 2016 22
  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting capability for renewable energy resources to excerpt an extreme amount from it, in addition to commercialization of classically costly renewable […]
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Global Gene Synthesis Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 24-May-2017        Price: US 3480 Onwards        Pages: 137
    Gene synthesis refers to chemically synthesizing a strand of DNA base-by-base. Unlike DNA replication that occurs in cells or by Polymerase Chain Reaction (PCR), gene synthesis does not require a template strand. Rather, gene synthesis involves the step-wise addition of nucleotides to a single-stranded molecule, which then serves as a template for creation of a complementary strand. Gene synthesis is the fundamental technology upon which the field of synthetic biology has been built. ......
  • Protein Assays Market by Product (Reagent, Kit, Instruments), Type (Dye Binding, Test Strip), Application (Drug Discovery, Disease Diagnosis), Technology (Colorimetric, Fluorescence), End User (Pharmaceutical, Clinical Lab) - Global Forecasts to 2022
    Published: 24-May-2017        Price: US 5650 Onwards        Pages: 126
    The protein assays market is expected to reach USD 1.42 billion by 2017 and is projected to grow at a CAGR of 11.1% between 2017 and 2022, to reach USD 2.41 billion in 2022. Protein assays are used in life science research to determine the total protein concentration. Estimation of protein concentration is necessary for protein purification, electrophoresis, cell biology, molecular biology, and research applications. The protein assays market is witnessing high growth due to factors such as i......
  • Global Cell Signaling Market Size, Status and Forecast 2022
    Published: 23-May-2017        Price: US 3300 Onwards        Pages: 93
    This report studies the global Cell Signaling market, analyzes and researches the Cell Signaling development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Merck KGaA - Thermo Fisher Scientific - Becton, Dickinson and Company - Beckman Coulter - Bio-Rad Laboratories - Perkinelmer - Qiagen - Cell Signaling Technology - Promega Corporatio......
  • Global Biophotonics Market Research Report 2017
    Published: 18-May-2017        Price: US 2900 Onwards        Pages: 129
    In this report, the global Biophotonics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Biophotonics in these regions, from 2012 to 2022 (forecast), covering - United States - EU - China - Japan ......
  • Global SNP Genotyping Market Size, Status and Forecast 2022
    Published: 18-May-2017        Price: US 3300 Onwards        Pages: 114
    This report studies the global SNP Genotyping market, analyzes and researches the SNP Genotyping development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Illumina - Affymetrix - Applied Biosystems - Agilent Technologies - Beckman Coulter - Roche - Qiagen - Luminex Corporation - Enzo Life Sciences - Bio-rad - Sequenom......
  • Global Procalcitonin Antibody Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 17-May-2017        Price: US 3480 Onwards        Pages: 122
    Procalcitonin (PCT) is a 116 amino acid residue protein with a molecular weight of approximately 13kDa. Procalcitonin is a peptide hormone mainly produced by the C cells of the thyroid and certain endocrine cells of the lung. Under normal expression conditions, procalcitonin is immediately cleaved into three specific fragments, an N terminal residue, calcitonin and katacalcin. It can be expressed in E. coliScope of the Report:This report focuses on the Procalcitonin Antibo......
  • North America Procalcitonin Antibody Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 17-May-2017        Price: US 4480 Onwards        Pages: 122
    Procalcitonin (PCT) is a 116 amino acid residue protein with a molecular weight of approximately 13kDa. Procalcitonin is a peptide hormone mainly produced by the C cells of the thyroid and certain endocrine cells of the lung. Under normal expression conditions, procalcitonin is immediately cleaved into three specific fragments, an N terminal residue, calcitonin and katacalcin. It can be expressed in E. coliScope of the Report:This report focuses on the Procalcitonin Antibo......
  • Depth Filtration Market by Media Type (Diatomaceous Earth, Activated Carbon, Cellulose), Product (Filter Cartridge, Capsule Filter), Application (Final Product Processing (Small Molecules, Biologics), Cell clarification) - Global Forecast to 2022
    Published: 17-May-2017        Price: US 5650 Onwards        Pages: 127
    The global depth filtration market is projected to reach USD 2.96 billion by 2022 from USD 1.70 billion in 2017, at a CAGR of 11.7% from 2017 to 2022. Increasing demand for biopharmaceuticals and increasing R&D expenditure in the biopharmaceutical industry are the major factors driving the growth of the global depth filtration market.Developing markets in the Asia-Pacific region such as Japan, China, India, South Korea, Taiwan, Australia, and Singapore are lucrative markets for dept......
  • Global Synthetic Biology Market Research Report 2017
    Published: 16-May-2017        Price: US 2900 Onwards        Pages: 104
    In this report, the global Synthetic Biology market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Synthetic Biology in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China -......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs